China Resources Pharmaceutical Group Ltd.
3320
Peringkat dalam Saham
#4271
China Resources Pharmaceutical Group Limited, an investment holding company,... China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operates retail pharmacies under the Teck Soon Hong brands. It distributes its products under the 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, Boya, and Kun Zhong Yao to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
Harga Saham
$0.59037955
Kapitalisasi Pasar
$3.71B
Perubahan (1 hari)
-0.86%
Perubahan (1 tahun)
-4.21%
Negara
HK
Perdagangan China Resources Pharmaceutical Group Ltd. (3320)
Kategori
Healthcare
Laba untuk China Resources Pharmaceutical Group Ltd. (3320)
Laba pada Jun 2026 TTM: $1.71B
Menurut laporan keuangan terbaru dari China Resources Pharmaceutical Group Ltd., laba saat ini perusahaan adalah $1.71B. Pada tahun 2023, perusahaan memperoleh laba sebesar $1.39B, peningkatan dibandingkan laba tahun 2022 sebesar $1.26B. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk China Resources Pharmaceutical Group Ltd. dari 2013 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2026 (TTM) | $1.71B | 13.87% |
| 2024 | $1.50B | 7.62% |
| 2023 | $1.39B | 10.35% |
| 2022 | $1.26B | 16.96% |
| 2021 | $1.08B | 18.19% |
| 2020 | $912.56M | 9.36% |
| 2019 | $834.45M | -28.83% |
| 2018 | $1.17B | 6.72% |
| 2017 | $1.10B | 5.89% |
| 2016 | $1.04B | -0.13% |
| 2015 | $1.04B | 16.37% |
| 2014 | $892.63M | 0.13% |
| 2013 | $891.51M | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| $1.35B | -20.87% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $26.37M | -98.45% |
US
|
